Abstract:INTRODUCTION AND OBJECTIVES: Docetaxel (DTX) is one of the primary drugs used for treating castration resistant prostate cancer (CRPC).Unfortunately, over time patients invariably develop resistance to DTX therapy and their disease will continue to progress.The mechanisms by which resistance develops is still incompletely understood.This study seeks to determine the involvement of miRNAs, specifically miR-181a, in DTX resistance in CRPC.METHODS: Total RNA from parental C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was submitted for small RNA deep sequencing.Data was analyzed to ascertain which miRNAs expressions were most altered in C4-2B TaxR cells compared to parental cells.Having identified an increase in miR-181a in resistant cells, its expression was modulated in C4-2B and C4-2B TaxR cells by transfecting them with miR-181a mimics or antisense, respectively.Following transfection, cell number was determined after 48 h with or without DTX.Cross resistance to cabazitaxel induced by miR-181a was also determined.Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity.Phospho-p53 expression was assessed by western blot and apoptosis was measured by ELISA in C4-2B TaxR cells with inhibited miR-181a expression with or without DTX.RESULTS: miR-181a is significantly upregulated in C4-2B TaxR cells compared to parental C4-2B cells as analyzed by small RNA sequencing.Overexpression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance.Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment with both DTX and cabazitaxel.miR-181a knockdown alone induced apoptosis in C4-2B TaxR cells which is further enhanced by DTX.We next assessed if miR-181a altered expression or activity of ABCB1, which is overexpressed/active in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug out of cells.We found that miR-181a does not impact ABCB1 expression or activity.Since we previously demonstrated that phospho-p53 can modulate DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B TaxR cells.Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53 expression, suggesting that miR-181a induced resistance to DTX is mediated by inhibition of phospho-p53 expression.CONCLUSIONS: Overexpression of mir-181a in C4-2B TaxR cells contributes to their resistance to DTX and inhibition of mir-181a expression can restore treatment response.This is due, in part, to modulation of p53 phosphorylation and induction of apoptosis.

Estrogen Receptor Α Confers Nab-paclitaxel Resistance in Breast Cancer by Promoting Mir199a-5P Maturation to Inhibit Caveolin 1 Translation

Estrogen receptor α inhibits Caveolin 1 translation by promoting m6A-dependent miR199a-5p maturation to confer nab-paclitaxel resistance

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Estrogen Receptor Alpha Mediates Breast Cancer Cell Resistance to Paclitaxel Through Inhibition of Apoptotic Cell Death.

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Estrogen Receptor Α Attenuates Therapeutic Efficacy of Paclitaxel on Breast Xenograft Tumors

Mir-375 is Upregulated in Acquired Paclitaxel Resistance in Cervical Cancer

Induction Of Paclitaxel Resistance By Er Alpha Mediated Prohibitin Mitochondrial-Nuclear Shuttling

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7

Reversal Effects of Raloxifene on Paclitaxel Resistance in 2 MDR Breast Cancer Cells

XBP1s Activates METTL3/METTL14 for ER-phagy and Paclitaxel Sensitivity Regulation in Breast Cancer

TXNDC17 Promotes Paclitaxel Resistance Via Inducing Autophagy in Ovarian Cancer

Mir-375 Mediated Acquired Chemo-Resistance in Cervical Cancer by Facilitating Emt

miR-141-3p promotes paclitaxel resistance by attenuating ferroptosis via the Keap1-Nrf2 signaling pathway in breast cancer

Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway

MP99-17 CIRCULARRNA-C17 ALTERS THE ANTI ANDROGEN-ENZALUTAMIDE RESISTANCE IN CASTRATION-RESISTANT PROSTATE CANCER VIA REGULATING ANDROGEN RECEPTOR VARIANT ARV7 EXPRESSION

Overexpression of Microrna-24 Increases the Sensitivity to Paclitaxel in Drug-Resistant Breast Carcinoma Cell Lines Via Targeting ABCB9.

Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC)

Isobavachalcone Sensitizes Cells to E2‐induced Paclitaxel Resistance by Down‐regulating CD44 Expression in ER+ Breast Cancer Cells

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis